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In humans, the onset of puberty is primarily
assessed by the physical changes that occur in
the genitalia of both sexes. In females, the
physical signs associated with the onset of
puberty are enlargement of the breasts,
ovaries, and uterus, as well as the growth of
pubic and axillary hair with apocrine secre-
tion. The process by which puberty occurs is
primarily regulated by the endocrine system
through its chemical messengers, speciﬁcally
the sexual hormones (1). The onset of puber-
tal changes at an earlier age than expected
may occur secondary to a varied group of dis-
orders. When the cause of premature sexual
development is unknown, the condition is
considered idiopathic. Premature sexual
development in the human female is present-
ly deﬁned as the appearance of any physical
change characteristic of puberty with onset
before 8 years of age (2).
Hyperplasia of breast tissue in neonates
is a normal physical ﬁnding that may be pre-
sent during the first 6 months of life as a
result of placental passage of maternal estro-
genic hormones. When this condition per-
sists beyond this period or occurs before 8
years of age in females, it is known as prema-
ture or precocious thelarche (Figure 1). The
majority of cases occur before 2 years of age.
Girls diagnosed with premature thelarche
have one or both breasts enlarged without
any other physical signs of the onset of
puberty (3).
Since 1979, pediatric endocrinologists in
Puerto Rico have detected an alarming
increase in the number of patients with
premature thelarche (4,5). Among the
hypotheses proposed to explain the observed
premature sexual development in this U.S.
Caribbean Island territory, the most contro-
versial theory associated thelarche with the
subject’s diet. Sáenz et al. (6) suggested that
dairy and meat products were contaminated
with anabolic estrogenic chemicals, which
are used for increasing muscle mass in cattle
and poultry. In 1985, studies conducted by
the U.S. Department of Agriculture in con-
junction with a scientiﬁc commission from
the Puerto Rico Department of Health led
to the conclusion that no abnormal levels of
the suspected chemicals were present in the
approximately 800 samples of meat and
dairy products that were analyzed (7). Other
theories are still under consideration, such as
the association with ovarian cysts, premature
endogenous production of sexual hormones,
and environmental contamination by phar-
maceutical waste products. These theories do
not establish a strong association with the
majority of the cases reported (8). Also, a
genetic predisposition of Puerto Rican girls
for developing premature thelarche is unlike-
ly. Investigation among this ethnic group in
the Philadelphia, Pennsylvania, area did not
reveal a similar pattern of early sexual devel-
opment (8). Moreover, other ethnic groups
living in Puerto Rico are also affected by the
condition (8).
In 1987, the Puerto Rico Department of
Health created by law the Premature
Thelarche and Early Sexual Development
(PTESD) Registry in response to the observed
increase in cases (9). This is the only world
registry created for the study of premature
sexual development in a human population.
The objectives of this epidemiologic surveil-
lance system are to deﬁne the epidemiologic,
clinical, and etiologic aspects of the different
manifestations of premature sexual develop-
ment on the island. Although the registry
was established in 1988, retrospective data to
1969 and prospective data to 1998 have
been collected. In this time period, 6,580
cases of premature sexual development have
been registered, of which 4,674 (71%) are
premature thelarche cases. Based on the data
accumulated by the registry, the estimated
annual average incidence rate of premature
thelarche in Puerto Rican girls 6–24 months
of age is 8 cases per 1,000 live female births
from 1984 to 1993 (10). This incidence 
is, to our knowledge, the highest ever report-
ed. Compared to a study conducted in
Minnesota (11), the incidence of premature
thelarche in the Puerto Rican female popula-
tion is 18.5 times higher. 
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Premature breast development (thelarche) is the growth of mammary tissue in girls younger than 8
years of age without other manifestations of puberty. Puerto Rico has the highest known incidence
of premature thelarche ever reported. In the last two decades since this serious public health anom-
aly has been observed, no explanation for this phenomenon has been found. Some organic pollu-
tants, including pesticides and some plasticizers, can disrupt normal sexual development in
wildlife, and many of these have been widely used in Puerto Rico. This investigation was designed
to identify pollutants in the serum of Puerto Rican girls with premature thelarche. A method for
blood serum analysis was optimized and validated using pesticides and phthalate esters as model
compounds of endocrine-disrupting chemicals. Recovery was > 80% for all compounds. We per-
formed ﬁnal detection by gas chromatography/mass spectrometry. We analyzed 41 serum samples
from thelarche patients and 35 control samples. No pesticides or their metabolite residues were
detected in the serum of the study or control subjects. Significantly high levels of phthalates
[dimethyl, diethyl, dibutyl, and di-(2-ethylhexyl)] and its major metabolite mono-(2-ethylhexyl)
phthalate were identiﬁed in 28 (68%) samples from thelarche patients. Of the control samples ana-
lyzed, only one showed signiﬁcant levels of di-isooctyl phthalate. The phthalates that we identiﬁed
have been classiﬁed as endocrine disruptors. This study suggests a possible association between
plasticizers with known estrogenic and antiandrogenic activity and the cause of premature breast
development in a human female population. Key words: endocrine-disrupting chemicals, phthalate
esters, premature thelarche. Environ Health Perspect 108:895–900 (2000). [Online 8 August 2000]
http://ehpnet1.niehs.nih.gov/docs/2000/108p895-900colon/abstract.html
CHILDREN’S HEALTH
ArticleIn the last decade, there has been a grow-
ing interest and concern for the study of the
impact of man-made chemicals on wildlife
and humans. These studies have suggested
that synthetic and naturally occurring sub-
stances in the environment may affect the nor-
mal function of the endocrine system. These
substances are also referred to as endocrine-
disrupting chemicals (EDCs). In wildlife,
alterations in sexual reproductive behavior
have been observed in areas of contamination
with EDCs. For example, malformations in
the sexual organs of alligators have been
reported in Lake Apopka, Florida, where
high concentrations of DDT and its degrada-
tion products have been detected (12,13),
and feminization of trout in the Great Lakes
has been associated with the high levels of
polychlorinated biphenyls (PCBs) in water
samples (14). Other studies have indicated
that many chemicals, including phthalate
esters, may affect development and reproduc-
tion, including germ cells, sperm motility,
chryptorchidism, and hypospadias, in labora-
tory animals (15–19). The specific mecha-
nisms by which these chemicals may affect
human health are unknown. Extrapolations
to humans of the effect of these substances
on wildlife are difﬁcult. A limited number of
reports (20–22) in the scientific literature
describe the accidental exposure of humans
to chemicals such as lindane and other
organochlorinated pesticides, dioxins, and
PCBs with known endocrine-disrupting
properties. The study of these exposures has
led to the conclusion that these compounds
can alter the female-to-male ratio in offspring
(20) and cause learning disabilities, behav-
ioral problems, suppression of the immune
system, and gynecomastia in the exposed
subjects (21–22).
At present, the cause of the observed high
incidence of premature sexual development in
Puerto Rico is unknown, and the long-term
consequences of the aberrant premature sexu-
al development in this population are also
unknown. Many of the chemicals that are
classified as EDCs have been imported or
produced in high quantities in Puerto Rico.
Until 1988, a total of 450 million pounds of
chlorinated pesticides were imported to the
island (23). Although many of these pesticides
are currently banned for use in U.S. territo-
ries, these pesticides are known to bioaccum-
mulate and to have a long persistence in the
environment. Also, many of these substances
such as phthalate esters, alkyl phenols, and
surfactants are present in commercial prod-
ucts commonly used for packaging, storing,
and preserving food (24). The environmental
load of plasticizers in Puerto Rico is
unknown, but it is assumed to be signiﬁcant
because of the high level of consumption of
dietary products in plastic containers import-
ed to the island. Based on the high exposure
to these substances in the general population
in Puerto Rico and the fact that exposure of
human fetuses, newborns, and young girls to
exogenous estrogenic chemicals may lead to
adverse effects in their sexual development,
we designed this study to search for known
EDCs in the serum of Puerto Rican girls with
premature thelarche. We focused speciﬁcally
on girls with premature thelarche because this
condition represents the majority (71%) of
the total cases of premature sexual develop-
ment reported on the island.
Methods
This research protocol was approved by
the San Juan City Hospital’s Institutional
Review Board before the initiation of the
study. 
Case and control subjects. Study subjects
were females from 6 months to 8 years of age
(mean age 31 months; median age 20
months), all diagnosed with premature the-
larche. We analyzed all samples from the-
larche patients taken from January 1994 to
April 1998. Control subjects were females
from 6 months to 10 years of age (mean age
70 months; median age 46 months). We
obtained control serum samples from the San
Juan City Hospital general clinical laborato-
ry. Control individuals did not have evidence
of premature sexual development or any
other endocrine disease (they were seen in the
institution for general pediatric care).
Serum samples were provided by the
Pediatric Endocrinology Section of the San
Juan City Hospital. This hospital is the only
municipal tertiary care public health institu-
tion for the city of San Juan and primarily
serves an indigent population, including the
subjects and controls for this study (25).
We used a number coding system for the
handling of samples during the analysis. To
assure confidentiality, subject’s names and
clinical data were not available to the
University of Puerto Rico’s Environmental
Analytical Chemistry Laboratory personnel
during the study. 
Moni-Trol samples. Moni-Trol (Dade, EF
Baragaño, Puerto Rico), a lyophilized product
derived from human serum, is available com-
mercially for optimization and calibration of
instrumentation in clinical laboratories. We
reconstituted the lyophilized samples as need-
ed with 5.00 mL of a carbonate diluent sup-
plied by the manufacturer. Samples were
stored at 4°C and protected from light.
Serum samples. Whole blood samples
were collected by venipuncture into glass
tubes with no chemical additives. After
collection, the samples were allowed to coagu-
late and were then centrifuged. Serum sam-
ples were stored at –23°C in glass tubes and
protected from light until analysis.
Optimization of the extraction procedure.
Moni-Trol samples were prepared, and 1 mL
samples were spiked with standard solutions
of diethyl phthalate (DEP) and dibutyl
phthalate (DBP) as model compounds of the
phthalate ester family. The spiked concentra-
tions were between 50 ppb and 25 ppm. The
samples were stored at 4°C protected from
light for 18 hr. After reaching room tempera-
ture, the samples were extracted with hexa-
ne/dichloromethane (8:1). The extracts were
concentrated to 1.0 mL with a ﬂow of nitro-
gen and 1 µL was injected into the gas chro-
matography/mass spectrometry (GC/MS)
system (HP 5890/5971; Hewlett Packard,
Wilmington, DE). The samples were ana-
lyzed by selected ion monitoring (SIM) using
a SPB-1 column (100% polydimethyl silox-
ane; Supelco, Bellefonte, PA). Samples were
heated to an initial temperature of 70°C for 4
min and then heated to 250°C at 10°C/min.
We compared the relative area of the peaks
for each standard to the area of standards in a
calibration curve generated under the same
conditions and calculated the percent of
recovery for each concentration. All method-
ology was tested using serum samples as well.
Serum samples were spiked with the model
compounds in concentrations ranging from
20 to 80 ppb.
Extraction of organic compounds from
serum samples. Serum samples were trans-
ported to the analytical laboratory in glass
tubes stored at 0°C. Precipitation of serum
and plasma proteins was accomplished by
adding 1 mL acetonitrile to 1.0 mL sample.
Five milliliters of the extraction mixture,
which consisted of an 8:1 solution of hexane
and dichloromethane, was added to each
sample. Samples were then submitted to
ultrasound extraction for 5 min in a sonicator
bath (Fisher Scientiﬁc, Cayey, Puerto Rico).
The phases were allowed to separate, and the
extract was transferred to a centrifuge tube.
The extraction procedure was performed
twice and the extracts were combined.
Concentration and analysis. The combined
extracts were concentrated to 0.5 mL with a
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Figure 1. Twenty-three-month-old Puerto Rican
girl with premature breast development (the-
larche).ﬂow of nitrogen. The concentrated extract (1
µL) was injected into the GC/MS system. The
samples were heated to an initial temperature of
70°C for 4 min and then raised to 130°C at
5°C/min and then to 250°C at a rate of
10°C/min. 
Special precautions. We applied essential
quality control standards to avoid incorrect
interpretation of results. This is particularly
important when the expected concentrations
of the analytes occur at trace levels. Phthalate
esters have been detected as interferences in
many chromatographic analyses (26,27). We
analyzed adequate sets of analytical blanks
before sample analysis; these included system
and solvent blanks as well as blanks for the
sampling device, pipettes, and storage tubes. 
Results
Optimization of the extraction and analysis
procedures. For the optimization of the
extraction procedure, Moni-Trol samples
spiked with DEP and DBP (concentrations
ranging from 50 ppb to 25 ppm) were
extracted and analyzed by GC/MS. We com-
pared the relative area for each compound in
the extract to the relative area for standards in
a calibration curve. The calibration curves had
R2 values > 0.99 for the model phthalates. We
calculated the amount extracted (in parts per
million) for each concentration and generated
recovery curves for each compound by plot-
ting the amount extracted as a function of the
amount of standard added to the sample. The
slope of the regression line gives the average
percent of recovery for each compound for
the concentration range. In Moni-Trol sam-
ples, the average percent recovery (± SD) for
DEP was 79.9 ± 0.4%, whereas the average
percent recovery for DBP was 88.2 ± 0.2%.
The method for extraction and analysis
showed excellent linear correlation (R2 values
> 0.99) for the concentration range tested.
When we tested the optimized method
using real blood serum instead of Moni-Trol
for the sample preparation and recovery
curves, we used concentrations ranging from
20 to 80 ppb; the recovery curves are present-
ed in Figure 2. Samples were analyzed by
GC/MS in the SIM mode. As calculated
from the recovery curves, the average percent
of recovery (± SD) was 118 ± 13% for DBP
and 88 ± 3% for DEP. 
Serum samples from thelarche patients
and control samples. We analyzed 41 samples
from patients diagnosed with premature the-
larche at the San Juan City Hospital’s
Pediatric Endocrinology Division and includ-
ed in the Premature Thelarche and Early
Sexual Development Registry of the Puerto
Rico Department of Health. We used a
GC/MS instrument operating in the scan
mode to analyze the samples. Figure 3 shows
a representative total ion chromatogram for
serum samples from study subjects. Figure 4
shows the extracted ion chromatogram for
m/z = 149 for the same chromatogram. The
m/z = 149 is one of the characteristic ions for
phthalate ester detection. As confirmed by
mass spectral data, four of the peaks in the
extracted ion chromatogram correspond to
compounds of the phthalate ester family.
Phthalate esters were consistently detected at
signiﬁcant concentration levels (ranging from
tens of parts per billion to units of parts per
million) in 28 of 41 (68%) serum samples
obtained from the thelarche patients. The
concentration of phthalate esters was
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Figure 2. Recovery curve for real serum samples spiked with (A) DEP (y = 0.8334x – 8.2971; R2 = 0.9939) and
(B) dibutyl phthalate (y = 1.18x – 17; R2 = 0.9504).
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Figure 4. Extracted ion chromatogram for the total
ion chromatogram in Figure 2. The peaks identi-
ﬁed as a, b, c, and d correspond to compounds of
the phthalate ester family.
Figure 3. Total ion chromatogram representative
of those obtained for samples from thelarche
patients.
Table 1. Average concentrations (µg/L) of phtha-
late esters in thelarche patient samples analyzed
by GC/MS in the SCAN mode.
Phthalate Sample Age Conc
ester ID no. (months) (µg/L)
DBP 1 19 115
2 19 134
3 17 182
4 47 276
52 0 9 1
63 7 4 3
72 4 7 9
82 0 5 7
9 36 252
10 20 120
11 26 125
35 32 38
39 21 15
DEP 2 19 8.0
31 7 3 7
44 7 1 9
52 0 1 2
63 7 2 2
Benzyl butyl  5 20 117
phthalate (BBP) 6 37 54
di-n-Octyl 15 36 438
phthalate (DOP)
di(2-Ethylhexyl) 3 17 1,809
phthalate 4 47 2,098
(DEHP) 5 20 565
6 37 578
7 24 1,602
8 20 1,447
9 36 935
10 20 907
11 26 607
12 10 681
13 83 855
25 78 633
26 12 721
27 29 392
28 72 326
29 15 444
30 21 470
31 18 532
32 16 417
33 36 468
34 32 353
35 19 246
37 20 454
38 16 187
39 16 349
Mono- 2 19 18
(2-ethylhexyl) 3 17 38
phthalate 4 47 33
(MEHP) 5 20 11
6 37 6.3
Abbreviations: conc, concentration; ID, identiﬁcation.ﬂow of nitrogen. The concentrated extract (1
µL) was injected into the GC/MS system. The
samples were heated to an initial temperature of
70°C for 4 min and then raised to 130°C at
5°C/min and then to 250°C at a rate of
10°C/min. 
Special precautions. We applied essential
quality control standards to avoid incorrect
interpretation of results. This is particularly
important when the expected concentrations
of the analytes occur at trace levels. Phthalate
esters have been detected as interferences in
many chromatographic analyses (26,27). We
analyzed adequate sets of analytical blanks
before sample analysis; these included system
and solvent blanks as well as blanks for the
sampling device, pipettes, and storage tubes. 
Results
Optimization of the extraction and analysis
procedures. For the optimization of the
extraction procedure, Moni-Trol samples
spiked with DEP and DBP (concentrations
ranging from 50 ppb to 25 ppm) were
extracted and analyzed by GC/MS. We com-
pared the relative area for each compound in
the extract to the relative area for standards in
a calibration curve. The calibration curves had
R2 values > 0.99 for the model phthalates. We
calculated the amount extracted (in parts per
million) for each concentration and generated
recovery curves for each compound by plot-
ting the amount extracted as a function of the
amount of standard added to the sample. The
slope of the regression line gives the average
percent of recovery for each compound for
the concentration range. In Moni-Trol sam-
ples, the average percent recovery (± SD) for
DEP was 79.9 ± 0.4%, whereas the average
percent recovery for DBP was 88.2 ± 0.2%.
The method for extraction and analysis
showed excellent linear correlation (R2 values
> 0.99) for the concentration range tested.
When we tested the optimized method
using real blood serum instead of Moni-Trol
for the sample preparation and recovery
curves, we used concentrations ranging from
20 to 80 ppb; the recovery curves are present-
ed in Figure 2. Samples were analyzed by
GC/MS in the SIM mode. As calculated
from the recovery curves, the average percent
of recovery (± SD) was 118 ± 13% for DBP
and 88 ± 3% for DEP. 
Serum samples from thelarche patients
and control samples. We analyzed 41 samples
from patients diagnosed with premature the-
larche at the San Juan City Hospital’s
Pediatric Endocrinology Division and includ-
ed in the Premature Thelarche and Early
Sexual Development Registry of the Puerto
Rico Department of Health. We used a
GC/MS instrument operating in the scan
mode to analyze the samples. Figure 3 shows
a representative total ion chromatogram for
serum samples from study subjects. Figure 4
shows the extracted ion chromatogram for
m/z = 149 for the same chromatogram. The
m/z = 149 is one of the characteristic ions for
phthalate ester detection. As confirmed by
mass spectral data, four of the peaks in the
extracted ion chromatogram correspond to
compounds of the phthalate ester family.
Phthalate esters were consistently detected at
signiﬁcant concentration levels (ranging from
tens of parts per billion to units of parts per
million) in 28 of 41 (68%) serum samples
obtained from the thelarche patients. The
concentration of phthalate esters was
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Figure 2. Recovery curve for real serum samples spiked with (A) DEP (y = 0.8334x – 8.2971; R2 = 0.9939) and
(B) dibutyl phthalate (y = 1.18x – 17; R2 = 0.9504).
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Figure 4. Extracted ion chromatogram for the total
ion chromatogram in Figure 2. The peaks identi-
ﬁed as a, b, c, and d correspond to compounds of
the phthalate ester family.
Figure 3. Total ion chromatogram representative
of those obtained for samples from thelarche
patients.
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late esters in thelarche patient samples analyzed
by GC/MS in the SCAN mode.
Phthalate Sample Age Conc
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2 19 134
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52 0 9 1
63 7 4 3
72 4 7 9
82 0 5 7
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Abbreviations: conc, concentration; ID, identiﬁcation.metabolite residues in samples. This opti-
mized method permits the use of the SIM
modality when lower detection limits are
required. This methodology may allow the
development of other analytical research
protocols that could result in enhanced
detection limits, thus offering investigators
the possibility of assessing levels of phthalate
esters and other known pollutants in blood
samples from the general population.
We detected high levels of phthalate
esters in 68% of the samples from thelarche
patients. DEP, DBP, and DEHP were
detected in levels ranging from tens of parts
per billion (nanograms per milliter) to units
of parts per million (milligrams per milliliter)
in case samples. MEHP, one of the major
metabolites of DEHP, was detected in ﬁve
case samples (Table 1). The presence of this
phthalate ester was not caused by sample
contamination, because contamination by a
metabolite rarely occurs. We detected DEHP
in 14% of the control samples. The concen-
tration of this phthalate in control samples
was significantly lower than the levels in
study samples (Table 2).
Many of the phthalate esters detected in
study samples have been shown to be estro-
genic when assayed by the recombinant yeast
screen test (32). Although phthalates have
low estrogenic activity compared to estradiol
and other potent estrogenic substances (33),
these chemicals may cause endocrine disrup-
tion through several mechanisms. Chemicals
with weak estrogenic activity may cause dis-
ruption in biologic systems if they act at criti-
cal periods of development (34). The
intrauterine period of human embrionic dif-
ferentiation and development is particularly
sensitive to weak estrogens. Besides their
estrogenic activity, phthalates such as DBP
have blocking antiandrogen action (35). If
these properties of phthalate esters play a role
in the cause of premature breast development
in Puerto Rican females, further research
should address this possibility. 
The detection of high levels of phthalate
esters in this group of Puerto Rican girls
could reﬂect an elevation in the exposure of
the general Puerto Rican population to these
substances. Further research will address this
issue. The total daily consumption of DEHP
from all sources of exposure has been estimat-
ed at 5.8 mg in the United States and 2.1 mg
in Japan (36). The most important sources of
exposure for children are ingestion of contam-
inated formulas, food, and water from contact
with plastic wrappings and containers and
mouthing of plastic toys and pacifiers
(36–38). There is mounting concern for
exposure to phthalate esters (specifically
DEHP), especially through polyvinyl chloride
plastic medical equipment. 
The present study provides the ﬁrst analyt-
ical evidence of the presence of plastic addi-
tives with known estrogenic activity in girls
with premature thelarche. In a study conduct-
ed in 1997 that included 17,077 girls,
Herman-Giddens et al. (39) reported that girls
in the United States are developing pubertal
characteristics at younger ages than previously
reported. These authors concluded that 
the possibility that the increasing use of certain
plastics and insecticides that degrade into sub-
stances that have estrogen-related physiological
effects on living things should be investigated in
relation to the earliest onset of puberty. 
The findings of this study cannot be
interpreted as the cause of premature the-
larche in Puerto Rican girls at present. It
may well be that the etiology of the various
manifestations of premature sexual develop-
ment (including thelarche) on this island is
multifactorial. Further research should be
performed to clarify if phthalate esters by
themselves, or in association with other
endogenous or exogenous estrogenic com-
pounds, are capable of inducing precocious
sexual development in animals and humans.
Other possible environmental cofactors relat-
ed to exposure should also be considered,
especially those unique to the Puerto Rican
environment. The following have already
been associated with premature sexual devel-
opment in Puerto Rico: the presence of ana-
bolic steroids in poultry (6) and consumption
of soy-based formula with a high phytoestro-
gen content by Puerto Rican infants (8). The
higher exposure to phthalate esters in the
Puerto Rican infant population is supported
by the high importation of plastic packaged
foods and because Puerto Rico is a tropical
island with year-round high temperature and
humidity, which promotes closed environ-
ments with the frequent use of air condition-
ers in homes and public buildings (36).
The issue of endocrine disruptors caus-
ing adverse health effects to humans and
wildlife is not free of controversy (40,41).
Other studies should address this issue, par-
ticularly that of critical stage susceptibility to
endocrine-disrupting chemicals and alter-
ations in sexual development of humans and
other animal species. If the hypothesis holds
true, premature sexual development in
Puerto Rico may prove to be an unfortunate
example of the impact of endocrine-disrupt-
ing environmental chemicals at a critical
stage of human development.
REFERENCES AND NOTES
1. Liwnicz BH, Liwnicz RG. On endocrine function. In:
Clinical Chemistry: Theory, Analysis and Correlation, 2nd
ed (Kaplan LA, ed). St. Lewis, MO:CV Mosby Company,
1989;607–619.
2. Sippell WG. Diagnosis and treatment of central preco-
cious puberty—can ﬁnal height be improved? Horm Res
41(suppl 2):14–15 (1994).
3. Kulin HE, Müller J. The biological aspects of puberty.
Pediatr Rev 17:75–86 (1996).
4. Pérez A. Precocious sexual development in Puerto Rico.
Lancet 1:1299–1300 (1982).
5. Bongiovanni AM. An epidemic of premature thelarche in
Puerto Rico. J Pediatr 103:245–246 (1983).
6. Sáenz CA, Bondiovanni AM, Conde L. An epidemic of
precocious development in Puerto Rican children. J
Pedriatr 107:393–396 (1985).
7. Montgomery EE. Unpublished data.
8. Freni-Titulaer LW, Cordero JF, Haddock L, Lebrón G,
Martínez R, Mills JL. Premature thelarche in Puerto Rico:
a search for environmental factors. Am J Dis Child
140:1263–1267 (1986).
9. Commonwealth of Puerto Rico. Regulation of the
Secretary of Health No. 64, 28 September 1989. 
10. Bourdony CJ. Premature Thelarche and Early Sexual
Development Registry. Annual report. San Juan, Puerto
Rico:Department of Health, 1998. 
11. Van Winter JT, Noller KL, Zimmerman D, Melton LJ.
Natural history of premature thelarche in Olmstead County,
Minesota, 1940 to 1984. J Pediatr 116:278–279 (1990).
12. Guillette LJ Jr, Gross TS, Masson GR, Matter JM,
Percival HF, Woodward AR. Developmental abnormalities
of the gonad and abnormal sex hormone concentrations
in juvenile alligators from contaminated and control lakes
in Florida. Environ Health Perspect 102:680–688 (1994).
13. Vonier PM, Crain DA, McLachlan JA, Guillette LJ Jr,
Arnold SF. Interaction of environmental chemicals with
the estrogen and progesterone receptors from the
oviduct of the American alligator. Environ Health
Perspect 104:1318–1322 (1996).
14. Colborn T, vom Saal FS, Soto AM. Developmental effects
of endocrine-disrupting chemicals in wildlife and
humans. Environ Health Perspect 101:378–384 (1993).
15. Siddiqui A, Srivastava SP. Effect of di(2-ethylhexyl)
phthalate administration on rat sperm count and on
sperm metabolic enzymes. Bull Environ Contam Toxicol
48:115–119 (1992).
16. Fredricsson B, Müller L, Pousette A, Westerholm R.
Human sperm motility is affected by plasticizers and
diesel particle extracts. Pharmacol Toxicol 72:128–133
(1993).
17. Imajima T, Shono T, Zakaria O, Suita S. Prenatal phtha-
late causes cryptorchidism postnatally by inducing
transabdominal ascent of the testis in fetal rats. J
Pediatr Surg 32:18–21 (1997).
18. Poon R, Lecavaliert P, Mueller R, Valli V, Procter B, Chu
I. Subchronic oral toxicity of di-n-octyl phthalate and
di(2-ethylhexyl) phthalate in the rat. Food Chem Toxicol
35:225–239 (1997). 
19. Arcadi R, Costa C, Imperatore C. Oral toxicity of DEHP
during pregnacy and suckling in the Long-Evans rat.
Food Chem Toxicol 36:963–974 (1998). 
20. Mocarelli P, Brambilla P, Gerthous PM, Patterson DG Jr,
Needham LI. Change in sex ratio with exposure to dioxin.
Lancet 348:409 (1996). 
21. Weisglas-Kuperus N, Sas TCJ, Koopman-Esseboom C,
van der Zuan CW, de Ridder MAJ, Keishuizen A,
Hooijkaas H, Sauer PJJ. Immunological effect of
Children’s Health • Phthalate esters in the serum of thelarche patients
Environmental Health Perspectives • VOLUME 108 | NUMBER 9 | September 2000 899
Table 4. Average concentrations (µg/L) of phthalate esters detected in blanks.
Sampling Distilled Extraction Glass  Plastic 
Phthalate ester butterﬂy (µg/L) water (µg/L) solvent (µg/L) tube (µg/L) tube (µg/L)
DBP ND 263 62 457 870
Benzyl butyl phthalate (BBP) ND 227 ND 149 ND
DEP ND ND 67 96 183
bis 1-Methylethyl phthalate ND ND ND ND 38
ND, not detected (concentration below 10 µg/L). background prenatal and postnatal exposure to dioxins
and polychlorinated biphenyls in Dutch infants. Pediatr
Res 38:404–410 (1995).
22. Sattin RW, Roisin A, Kafrissen ME, Dugan JB, Farer LS.
Epidemic of gynecomastia among illegal Haitian
entrants. Public Health Rep 99:504–510 (1984).
23. Quiñones A. Importación de plaguicidas a Puerto Rico
[M.S. Thesis]. San Juan, Puerto Rico:University of Puerto
Rico, 1992. 
24. Ross G. 1,001 Chemicals in Everyday Products. New
York:Van Nostrand Reinhold, 1994.
25. Puerto Rico Planning Board. Unpublished data.
26. Leung S, Giang BY. Phthalate esters as potential conta-
minants during GC analysis of environmental samples
using electron capture and mass spectrometric detec-
tors. Bull Environ Contam Toxicol 50:528–532 (1993).
27. López-Avila V, Milanés J, Constantine F, Beckert WF.
Typical phthalate ester contamination incurred using EPA
method 8060. J Assoc Off Anal Chem 73:709–720 (1990).
28. Kavlock RJ, Daston GP, DeRosa C, Fenner-Crisp P, Gray
LE, Kaattari S, Lucier G, Luster M, Mac MJ, Maczka C, et
al. Research needs for the risk assessment of health and
environmental effects of endocrine disruptors: a report
of the U.S. EPA-sponsored workshop. Environ Health
Perspect 104(suppl 4):715–740 (1996).
29. Hileman B. Environmental hormone disrupters focus of
major research initiatives. Chem Eng News 74:28–35
(1996). 
30. Patlak M. A testing deadline for endocrine disrupters.
Environ Sci Technol 30:540A–544A (1996).
31. Malik S, Kenny M, Ahmad S. A convenient method to mea-
sure di-2-ethylhexyl phthalate from the serum of hemodial-
ysis patients. Toxicol Environ Chem 37:333–337 (1993).
32. Harris CA, Henttu P, Parker MG, Sumpter JP. The estro-
genic activity of phthalate esters in vitro. Environ Health
Perspect 105:802–811 (1997).
33. Jobling S, Reynolds T, White R, Parker MG, Sumpter JP.
A variety of environmentally persistent chemicals,
including some phthalate plasticizers, are weakly estro-
genic. Environ Health Perspect 103:582–587 (1995).
34. Colborn T, Clement C. Chemically-Induced Alterations in
Sexual and Functional Development: The Wildlife/Human
Connection. Princeton, NJ:Princeton Scientiﬁc Publishing
Co., 1992.
35. Mylchreest E, Cattley R, Foster P. Male reproductive
tract malformations in rats following gestational and
lactational exposure to di(n-butyl)phthalate: an antian-
drogenic mechanism? Toxicol Sci 43:47 (1998).
36. Giust JA, Seipelt T, Anderson BK, Deis DA, Hinders JD.
Determination of bis(2-ethylhexyl) phthalate in cow’s
milk and infant formula by high performance liquid chro-
matography. J Agric Food Chem 38:415–418 (1990).
37. Rastogi SC. Gas chromatographic analysis of phthalate
esters in plastic toys. Chromatographia 47:724–726 (1998).
38. Marín ML, López J, Sánchez A, Vilaplana J, Jiménez A.
Analysis of potentially toxic phthalate plasticizers used in toy
manufacturing. Bull Environ Contam Toxicol 60:68–73 (1998).
39. Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony
CJ, Bhapkar MV, Koch GG, Hasemeier CM. Secondary
sexual characteristics and menses in young girls seen in
office practice: a study from the Pediatric Research in
Ofﬁce Settings network. Pediatrics 99:505–512 (1997).
40. Safe S. Environmental and dietary estrogens and human
health: is there a problem? Environ Health Perspect
103:346–351 (1995).
41. Zacharewski T, Meek M, Clemons J, Wu Z, Fielden,
Mathews J. Examination of the in vitro and in vivo estro-
genic activities of eight commercial phthalate esters.
Toxicol Sci 46:282–293 (1998). 
Children’s Health • Colón et al.
900 VOLUME 108 | NUMBER 9 | September 2000 • Environmental Health Perspectives